Clinical Trial

Safety and Efficacy Study of YZJ-1139 Tablets in Insomnia Disorder

Completed Phase 3
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to assess efficacy of YZJ-1139 for 28 days in adult subjects with insomnia disorder. Efficacy will be evaluated on objective and subjective sleep parameters.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-09; most recent amendment 2026-06-26.
Status change: Recruiting → Completed 2026-06-26
Trial Details
NCT Number NCT06975514
Lead Sponsor Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Conditions Insomnia Disorder
Enrollment 61 participants
Start Date 2025-03-25
Primary Completion 2025-07-21 (estimated)
Study Completion 2025-08-14 (estimated)
Updated on ClinicalTrials.gov 2026-06-29